413 F.Supp.3d 498
M.D. La.2019Background
- Plaintiff Stanley P. Baudin alleges he developed gastric cancer after long‑term use of the prescription PPI Nexium and sues AstraZeneca entities and Merck as manufacturers/marketers.
- Claims pleaded under Louisiana law: LPLA causes of action (design defect, failure to warn, breach of express warranty), redhibition (economic loss), and various fraud/negligent‑misrepresentation counts.
- Case was removed to federal court on diversity jurisdiction; Louisiana substantive law applies.
- Defendants moved to dismiss under Rules 12(b)(6) and 8, arguing LPLA exclusivity bars non‑LPLA tort claims, and that the complaint fails to plausibly plead design defect, inadequate warning, breach of warranty, redhibition, and Rule 8 sufficiency.
- The complaint contains extensive factual and scientific allegations linking PPIs/Nexium to gastric cancer and identifies H2‑blockers as alleged safer alternatives.
- Court: LPLA precludes non‑LPLA tort claims (fraud, negligent misrepresentation, non‑economic redhibition) — those are dismissed with prejudice; but design‑defect, failure‑to‑warn, breach‑of‑express‑warranty, and redhibition (economic loss) claims survive. Plaintiff given 30 days to amend remaining state law claims as to deficiencies.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether LPLA precludes non‑LPLA tort claims | Baudin conceded LPLA governs manufacturer liability but sought to preserve common‑law fraud, negligent misrepresentation, and non‑economic redhibition | AstraZeneca/Merck: LPLA is exclusive; non‑LPLA torts barred | Court: LPLA exclusivity applies — fraud, negligent misrepresentation, and non‑economic redhibition dismissed with prejudice |
| Whether complaint plausibly pleads a design‑defect claim under LPLA | Alleged alternative, safer design exists (H2 antagonists), detailed scientific/epidemiologic allegations linking Nexium to gastric cancer and distinguishing alternatives | Defendants: allegations are conclusory, merely identify other products and statutory labels without a specific alternative design or burdens/utility analysis | Court: pleadings sufficiently allege an alternative design and risk/benefit plausibly — design‑defect claim survives |
| Whether failure‑to‑warn claim is plausibly pleaded (learned intermediary) | Complaint quotes Nexium labeling and alleges inadequate warnings and that adequate warnings would have changed physician prescribing and plaintiff’s use | Defendants: allegations conclusory; plaintiff didn’t name prescribing physician or specify the adequate warning; causation insufficient | Court: identification of prescribing physicians by name not required; label excerpts + detailed allegations suffice to plead inadequacy and causation — failure‑to‑warn claim survives |
| Whether breach of express warranty and redhibition (economic) claims survive | Plaintiff alleges express warranties Nexium was "safe," reliance by physicians/patient, economic losses sought; claims tied to alleged product defect | Defendants: allegations are boilerplate; do not specify exact warranty language or seller details; redhibition improperly pleaded | Court: factual allegations of a promotional scheme and specific safety allegations suffice for express warranty; redhibition limited to economic loss preserved; both claims survive |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (pleading must state a plausible claim)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (legal conclusions not entitled to assumption of truth)
- In re Katrina Canal Breaches Litig., 495 F.3d 191 (5th Cir. 2007) (12(b)(6) pleading standard discussion)
- Roman v. W. Mfg., Inc., 691 F.3d 686 (5th Cir. 2012) (LPLA design‑defect framework)
- Stahl v. Novartis Pharms. Corp., 283 F.3d 254 (5th Cir. 2002) (learned intermediary doctrine in failure‑to‑warn context)
- Wheat v. Pfizer, Inc., 31 F.3d 340 (5th Cir. 1994) (LPLA causation/warning principles)
- Boutte v. Stryker Biotech, LLC, 67 F. Supp. 3d 732 (M.D. La. 2014) (sufficient pleading of a promotional/warranty scheme in products case)